Oncolytics Biotech (TSE:ONC) Hits New 12-Month Low – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low on Tuesday . The company traded as low as C$0.86 and last traded at C$0.87, with a volume of 254159 shares. The stock had previously closed at C$0.93.

Analyst Upgrades and Downgrades

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The stock has a market capitalization of C$70.14 million, a P/E ratio of -2.54 and a beta of 1.35. The company has a fifty day simple moving average of C$1.10 and a two-hundred day simple moving average of C$1.30.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.